Engineering Better Cell Therapies for Cancers

March 29, 2023

Cell therapies are revolutionizing the way cancers are treated, but existing cell therapies have their limits. They have been more successful at treating hematologic tumors than solid tumors, and they can sometimes cause serious side effects, such as the destruction of antibodies or what’s known as cytokine storms in which the immune system gets over-revved and attacks healthy cells. Triumvira Immunologics is developing autologous and allogeneic T-Cell therapies that it believes can address the limitations of existing cell therapies and be used to treat both liquid and solid tumors.

We spoke to Paul Lammers, CEO of Triumvira, about the company’s platform technology, why it’s robust and versatile, and why its lead indication is for cancer where effective treatments already exist.